Navigation Links
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Date:3/10/2011

PARIS and TARRYTOWN, N.Y., March 10, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).  The data showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the pre-specified criteria for the primary endpoint of improvement in overall survival compared with a regimen of docetaxel plus placebo (HR=1.01, CI: 0.868 to 1.174).  The addition of aflibercept to docetaxel demonstrated activity as measured by key secondary endpoints of the study: progression free survival (PFS) (HR=0.82, CI: 0.716 to 0.937) and an overall objective response rate (ORR) of 23.3% in the aflibercept arm compared to 8.9 percent in the placebo arm.

The treatment emergent adverse events (AEs) on the aflibercept arm with an incidence that was 10 percent greater than the control arm were stomatitis, weight decrease, hypertension, epistaxis and dysphonia. Grade 3 or 4 AEs that occurred at a frequency of at least 5 percent in patients who received aflibercept were fatigue, stomatitis, disease progression, hypertension, febrile neutropenia, dyspnea, neutropenia, and asthenia.  AEs leading to treatment discontinuation occurred in 27.2 percent of patients in the aflibercept arm compared to 14.6 percent in the placebo arm.  The types and frequencies of AEs reported in the aflibercept treatment arm were generally consistent with those reported in previous studies with anti-VEGF agents.  

The companies will conduct a detailed analysis of the efficacy and safety results of the VITAL study.  Full results will be presente
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... LEWIS CENTER, Ohio , May 22, 2013 ... of Opioid Defense Manager™ (ODM).  Launched in November ... Medical,s revolutionary managed care program to stop the ... ODM is a proactive, customized program designed to ... drug use while maintaining the necessary balance to ...
(Date:5/22/2013)... , May 22, 2013  MGT Capital Investments, Inc. ... present at the Second Annual Marcum LLP MicroCap Conference ... York City at the Grand Hyatt Hotel.  ... Executive Officer, will update investors and answer questions. ... Company,s presentation is scheduled to begin at 9:30 a.m. ...
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
Breaking Medicine Technology:Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4
(Date:5/22/2013)... York, New York (PRWEB) May 22, 2013 ... the nation’s first trial involving a da Vinci lawsuit, ... the case, the family of a man who allegedly died ... seeking more than $8 million in damages from Intuitive Surgical, ... down its physician training program for the da Vinci Surgical ...
(Date:5/22/2013)... Miami, FL (PRWEB) May 22, 2013 ... New York Daily News article titled "Breast ... better sports bras could help." According to ... and found that a substantial amount suffer from breast ... sports bra to correct the issue. , Zensah ...
(Date:5/22/2013)... Pass, OR (PRWEB) May 22, 2013 People ... and it is leading to water shortages. In much of ... luxury, according to water advocate, Sharon Kleyne. She warns against ... conserve the water that is available so easily in the ... Kleyne Hour Power of Water radio show, heard live or ...
(Date:5/22/2013)... May 22, 2013 Diversity Focus and ... This! The performance promotes awareness that physical disabilities ... Handicap This! performance will be held Friday, June 14th ... auditorium. Tickets for Handicap This! can be purchased ... audiences measure the level to which their mind is ...
(Date:5/22/2013)... challenges previous research that suggests umpire discrimination exists ... collaboration between researchers at U-M and the universities ... controversial argument over whether MLB umpires discriminate by ... same race. It found little statistical evidence to ... of sport management at the U-M School of ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 3Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2
... other members of bipartisan,group of Capitol Hill veterans ... trade, labor and employment,and tax policy, WASHINGTON, ... campaign, one thing is certain: change is coming ... regulated by the federal government,will face a new ...
... Pa., Nov. 4 /PRNewswire/ Capital BlueCross announced the,launch of ... and the,Lehigh Valley, called BlueCross Dental. No specific date ... but it is slated to be available to,customers in ... become the most popular,dental plan in our region because ...
... Misonix, Inc.,(Nasdaq: MSON ), today announced ... leading supplier of after market products, services,and test ... ultrasound,probe study in Sweden at the country,s annual ... paper was presented by the School,for Technology and ...
... research published in the November 4, 2008 issue of ... Academy of Neurology, found that ADHD affects the motor ... improvement of motor skills in children with and without ... Md. found that girls with ADHD and their typically ...
... Inc.,(NYSE: HSP ), a global specialty pharmaceutical ... Begley, chairman and chief,executive officer, and Thomas E. ... will make a formal presentation at the 2008,Annual ... 12, 2008, in,Phoenix., The presentation is scheduled ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Pharmaceuticals, will present at,two upcoming investor conferences, one ... Suisse., Dr. Bell will present at Deutsche ... p.m. Eastern Time, on Tuesday, November 11,2008. Dr. ...
Cached Medicine News:Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 2Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 3Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 3Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 4Health News:Study finds ADHD affects motor skills of boys more than girls 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: